- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
San Clemente Today
By the People, for the People
Financial Analysis: Vyome (HIND) versus Its Rivals
Comparing the medical device company Vyome to its industry competitors
Published on Feb. 15, 2026
Got story updates? Submit your updates here. ›
This article provides a financial analysis comparing Vyome (NASDAQ:HIND), a publicly-traded company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry, to its 27 competitors. The analysis looks at factors like institutional ownership, insider ownership, profitability, valuation, and more to see how Vyome stacks up against its peers.
Why it matters
Understanding how a company performs relative to its industry competitors is important for investors to assess the company's overall health and growth potential. This analysis sheds light on Vyome's strengths and weaknesses compared to similar medical device firms, which can inform investment decisions.
The details
The analysis finds that Vyome has slightly lower institutional and insider ownership compared to the industry average. However, Vyome has stronger profitability metrics like net margins, return on equity, and return on assets than its competitors. Vyome also trades at a lower price-to-earnings ratio, indicating it may be more affordable than other firms in the space. On the other hand, Vyome's revenue and earnings per share are lower than the industry average. Additionally, Vyome's share price is more volatile, with a beta of 1.5 compared to the industry average of 1.76.
- The analysis is based on data reported as of February 15, 2026.
The players
Vyome
A publicly-traded company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry.
ReShape Lifesciences Inc.
A medical device company that provides products and services to manage and treat obesity and metabolic diseases.
The takeaway
This analysis highlights that while Vyome may be more affordable than its peers, it faces some challenges around lower institutional and insider ownership as well as more volatile share price performance. Investors will want to weigh these factors against Vyome's stronger profitability metrics when considering the company as an investment.
